MannKind Corporation develops and sells inhaled therapeutic products for endocrine and orphan lung diseases in the US. Its products include Afrezza, an inhaled insulin for diabetes, and Thyquidity for hypothyroidism. The company has a license and collaboration agreement with United Therapeutics Corporation and an agreement with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI. MannKind Corporation was founded in 1991 and is based in Westlake Village, California.